Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease

BACKGROUND: Tegoprazan is a novel, fast‐ and long‐acting potassium‐competitive acid blocker that suppresses gastric acid secretion, which could benefit patients with non‐erosive reflux disease (NERD), a type of gastroesophageal reflux disease. AIM: To evaluate the efficacy and safety profiles of teg...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Han, Cho, Kwang Bum, Chun, Hoon Jai, Lee, Sang Woo, Kwon, Joong Goo, Lee, Dong Ho, Kim, Sang Gyun, Jung, Hwoon‐Yong, Kim, Ji Won, Lee, Joon Seong, Park, Hyojin, Choi, Suck Chei, Jee, Sam Ryong, Kim, Hyun‐Soo, Ko, Kwang Hyun, Park, Seun Ja, Lee, Yong Chan, Park, Soo Heon, Kim, Ah Rong, Kim, Eun Ji, Park, Hyun Wook, Kim, Bong Tae, Song, Geun Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Tegoprazan in Non‐erosive Reflux Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361733/
https://www.ncbi.nlm.nih.gov/pubmed/34227708
http://dx.doi.org/10.1111/apt.16477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361733/
https://www.ncbi.nlm.nih.gov/pubmed/34227708
http://dx.doi.org/10.1111/apt.16477

Ejemplares similares